Ultimately, these insights may pave the way for innovative interventions targeting PCSK9 and LDLR gene expression in obesity and metabolic disorders, offering promising avenues to enhance lipid profiles and mitigate cardiovascular risk in obese individuals. This evidence concerns the gene LDLR and obesity due to melanocortin 4 receptor deficiency.